S X Sun1, H H Guo2, J Zhang3, B Yu2, K N Sun1, Q H Jin1. 1. Department of Orthopedics, Affiliated Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China. 2. Ningxia Medical University, Ningxia Hui Autonomous Region, China. 3. Institute of Pathology, Xi'an Jiaotong University, Xi'an Shaanxi, China.
Abstract
A previous study showed that BMP-2 (bone morphogenetic protein-2) and wear debris can separately support osteoclast formation induced by the receptor activator of NF-κB ligand (RANKL). However, the effect of BMP-2 on wear debris-induced osteoclast formation is unclear. In this study, we show that neither titanium particles nor BMP-2 can induce osteoclast formation in RAW 264.7 mouse leukemic monocyte macrophage cells but that BMP-2 synergizes with titanium particles to enhance osteoclast formation in the presence of RANKL, and that at a low concentration, BMP-2 has an optimal effect to stimulate the size and number of multinuclear osteoclasts, expression of osteoclast genes, and resorption area. Our data also clarify that the effects caused by the increase in BMP-2 on phosphorylated SMAD levels such as c-Fos expression increased throughout the early stages of osteoclastogenesis. BMP-2 and titanium particles stimulate the expression of p-JNK, p-P38, p-IkB, and P50 compared with the titanium group. These data suggested that BMP-2 may be a crucial factor in titanium particle-mediated osteoclast formation.
A previous study showed that BMP-2 (bone morphogenetic protein-2) and wear debris can separately support osteoclast formation induced by the receptor activator of NF-κB ligand (RANKL). However, the effect of BMP-2 on wear debris-induced osteoclast formation is unclear. In this study, we show that neither titanium particles nor BMP-2 can induce osteoclast formation in RAW 264.7mouseleukemic monocyte macrophage cells but that BMP-2 synergizes with titanium particles to enhance osteoclast formation in the presence of RANKL, and that at a low concentration, BMP-2 has an optimal effect to stimulate the size and number of multinuclear osteoclasts, expression of osteoclast genes, and resorption area. Our data also clarify that the effects caused by the increase in BMP-2 on phosphorylated SMAD levels such as c-Fos expression increased throughout the early stages of osteoclastogenesis. BMP-2 and titanium particles stimulate the expression of p-JNK, p-P38, p-IkB, and P50 compared with the titanium group. These data suggested that BMP-2 may be a crucial factor in titanium particle-mediated osteoclast formation.
The biological response to wear particles at the bone-implant interface is considered
the main cause of aseptic loosening and osteolysis (1,2) by increasing osteoclastogenesis
and bone resorption (3,4). Macrophages phagocytize particles and secrete proinflammatory
factors such as tumor necrosis factor-α (TNF-α), which are thought to mediate the
differentiation of osteoclast precursor cells and play a fundamental role in this
pathologic response (5,6). A recent study showed that bone morphogenetic protein-2 (BMP-2),
a member of the superfamily of transforming growth factor beta (TGF-β) ligands, could
also affect osteoclastogenesis (7,8). It seems to have a double effect on osteoclast
formation. In the presence of osteoblasts, BMPs can indirectly suppress
osteoclastogenesis by decreasing the receptor activator of NF-κB ligand (RANKL) released
by osteoblasts (9,10). In the absence of osteoblasts, BMP-2 appears to directly increase
osteoclast formation and survival (11-13).However, neither wear particles nor BMP-2 alone can induce osteoclast recruitment
without RANKL, which is essential for osteoclastogenesis (14,15). RANKL is a member of
the TNF superfamily and is expressed on the surface of osteoblast-lineage cells. It
functions by interacting with its receptor, RANK, on osteoclast precursors through the
RANK/RANKL/osteoprotegerin axis, which regulates osteoclast maturation and activation
(16,17).Mitogen-activated protein kinase (MAPK) family members (JNK, p38, and ERK) and AP-1
(c-Fos and c-Jun) are well known to be essential to osteoclast formation, and inhibitors
of these pathways have been shown to reduce osteoclast formation (18,19). At the molecular
level, MAPK and c-Fos have been shown to become activated following wear debris
treatment of macrophages (20,21). NF-κB is also important in osteoclastogenesis,
and wear debris can activate NF-κB in cultured macrophages (22). A deficiency of NF-κB1 in mice protects against
titanium-induced calvarial osteolysis (23).Although these pathways have been well established to exert multiple effects to promote
osteoclast formation, the significance of BMP signaling in wear debris-induced
osteoclast formation is not clear. Some reports have shown that the activity of TGF-β is
not exclusive to the SMAD signaling pathway and that it can regulate other signaling
pathways, such as p38, JNK, AP-1, and NFκB (24-27). Similar to TNF, TGF-β may
synergistically potentiate the action of RANKL by such pathways. Interestingly, blocking
the action of TGF-β also blocks RANKL-dependent osteoclastogenesis (28). This observation implies that TGF-β may be an
essential factor for osteoclast formation.Although the application of BMPs during orthopedic procedures has been found to promote
a transient increase in osteoclast numbers and osteoclastic bone resorption (13), the effect of BMP-2 on wear debris-induced
osteoclast formation is unclear. The aims of this study were to determine the effect of
BMP-2 on wear debris-induced osteoclast formation, and to determine whether the activity
of BMP-2 involves the SMAD pathway and/or SMAD-independent pathway. Because osteoclasts
play a key physiological and pathological role in osteoporosis, we used RAW 264.7
macrophage-like cells, which are osteoclast precursors, to perform this study (29).
Material and Methods
Cultured cells and reagents
Mouse monocyte/macrophage RAW 264.7 cells (American Type Culture Collection, Cell
Bank of Chinese Academy of Sciences, China) were cultured in Dulbecco's modified
Eagle's medium with glutaMAX (Gibco Invitrogen, USA) containing 10% fetal bovine
serum (Hyclone, USA) and 1% antibiotic-antimycotic (Gibco Invitrogen) in a humidified
atmosphere of 5% CO2 at 37°C. RAW 264.7 cells were grown to 60-70%
confluency, counted and cultured on 6-well tissue culture plates (4×105
cells/well). The cells were pretreated with 30 ng/mL RANKL (R&D Systems, USA) for
1 h and stimulated with titanium particles alone, 50 ng/mL BMP-2 alone (R&D
Systems), or 50 ng/mL BMP-2 and 150 µg/mL titanium particles for the indicated times.
The supernatants or cells were collected for further analysis.
Titanium particles
The titanium particles, average diameter 5 μm, were kindly provided by the Zimmer
Company (USA). The particles were rinsed in ethanol three times and then in PBS three
times. Next, the particles were mixed with the culture medium at concentrations of
10, 50, 100, 150, and 200 µg/mL. The titanium suspensions were sonicated for 30 min
before using.
Cell viability assay
The cells were plated on 96-well plates (Corning Incorporated, USA) at a density of
104 cells/well. After treatment with 30 ng/mL RANKL, the cells were
incubated with 150 µg/mL titanium particles alone or 50 ng/mL BMP-2 and 150 µg/mL
titanium particles for 3 days. Osteoclast viability was assessed using an MTT assay
(Sigma, USA) according to the manufacturer's instructions.
For differentiation of RAW 264.7 cells into osteoclasts, the cells were seeded and
cultured on 96-well plates (104 cells/well). Multinucleated osteoclasts
were observed at day 8. The TRAP-staining kit (Sigma) was used to evaluate TRAP
expression. The TRAP(+) multinucleated cells that contained three or more nuclei were
counted as osteoclasts using optical microscopy, and ImagePro Plus was used to
quantify the data.
Pit resorption assay
The effects of osteoclastic modulators were tested with the 24-well Corning Osteo
Assay (Corning Incorporated). The RAW 264.7 cells (approximately 5000 cells per well)
were transferred to each well of a 24-well Corning Osteo Assay plate. The plates were
incubated at 37°C in a humidified atmosphere with 5% CO2 for 8 days with a
change of medium on day 3. After 8 days, the plates were washed with 6% sodium
hypochlorite to remove the cells. Individual pits or multiple pit clusters were
observed using a microscope at 10× magnification.
Enzyme-linked immunosorbent assay (ELISA)
To examine TNF-α secretion, the RAW 264.7 cells were plated on 96-well plates
(104 cells/well) with 30 ng/mL RANKL for 1 h and then incubated for 1
day with 50 ng/mL BMP-2 alone or 50 ng/mL BMP-2 and 150 µg/mL titanium particles in
the presence of 30 ng/mL RANKL for 1 day. The levels of TNF-α secreted into the cell
culture supernatant were measured using ELISA kits (Shanghai Lianshuo Biological
Technology, China) according to the manufacturer's instructions.
Quantitative real-time PCR
Total RNA was isolated from cells using the TRIzol reagent (Gibco Invitrogen) and
quantified by NanoDrop 2000 (Thermo Scientific, USA). The RNA was reverse transcribed
to cDNA with the RevertAid First-Strand cDNA synthesis kit (Fermentas, China).
Quantitative real-time PCR was then performed in triplicate using the Bio-Rad iQ5
gradient real-time PCR system. All reactions were performed in a 25-μL reaction
volume containing 12.5 μL SYBR Premix Ex Taq™ II (TaKaRa, Japan) according to the
manufacturer's instructions. The following primer sequences were used:
TRAP (forward) 5′-GCAGCCAAGGAGGACTAC-3′ and (reverse)
5′-CCCACTCAGCACATAGCC-3′; NFATc1 (forward)
5′-TCTTCCGAGTTCACATCC-3′ and (reverse) 5′-ACAGCACCATCTTCTTCC-3′;
Cathepsin K (forward) 5′-CAGAACGGAGGCATTGAC-3′ and (reverse)
5′-CGATGGACACAGAGATGG-3′; GAPDH (forward)
5′-TCAACGGCACAGTCAAGG-3′ and (reverse) 5′-ACTCCACGACATACTCAGC-3′.
Western blot analysis
Whole cells were extracted in radioimmunoprecipitation assay buffer containing
protease and phosphatase inhibitors (Sigma-Aldrich, USA). The protein concentration
was measured with a bicinchoninic acid protein assay kit following the manufacturer's
instructions. The proteins were resolved by SDS-PAGE, transferred to a polyvinylidene
fluoride membrane and incubated overnight at 4°C with primary antibodies against
phospho (P)-SMAD 1/5/8 (Cell Signaling, USA), SMAD 1/5/8 (Abcam, USA), NFKB1 (Cell
Signaling), c-Fos (Cell Signaling), p-P38 (Cell Signaling), p-JNK and p-IkB (Anbobio,
China). The same membranes were probed with anti-β-actin antibodies (Sigma) to
normalize protein loading in each lane. Subsequently, the blots were washed in
Tris-buffered saline with Tween (10 mM Tris-HCl, 50 mM NaCl, and 0.25% Tween-20) and
incubated with the secondary antibody. Immunoreactive bands were visualized using an
ECL Plus substrate (GE Healthcare Life Sciences, China).
Statistical analysis
All experiments were performed in triplicate. Significant differences were determined
using one-way ANOVA with a least-significant difference test. Differences of
P<0.05 were considered to be significant.
Results
Effect of titanium particles on RAW 264.7 cell differentiation
To evaluate the effects of the titanium particles on the RANKL-mediated osteoclast
differentiation of RAW 264.7 cells, we cultured the cells in the presence of
suboptimal levels of 30 ng/mL RANKL and titanium particles. After 1 day, we measured
TNF-α protein expression, which plays a major role in activating osteoclast
recruitment (5,6), and after 5 days, we measured TRAP gene expression, a
hallmark of osteoclasts (30). The titanium
particles increased TNF-α expression in a dose-dependent manner and showed an optimum
effect at a concentration of 150 µg/mL (Figure
1A). There were no significant differences in TRAP expression between the
different concentrations of titanium particles and the control (Figure 1B). The TRAP stain also failed to produce any
differentiated osteoclasts in each group (data not shown). This result indicated that
the titanium particles failed to induce the differentiation of osteoclast precursors
in the presence of RANKL.
Figure 1
Expression of TNF-α and TRAP. A, ELISA showed the protein
levels of TNF-α. RAW 264.7 cells were pretreated with titanium particles at
different concentrations for 1 day. Data are reported as means±SD. *P<0.05;
**P<0.001; ***P<0.0001 (one-way ANOVA). B, Expression of
the TRAP gene. The RAW 264.7 cells were pretreated with 30
ng/mL RANKL for 1 h and then treated with different concentrations of titanium
particles for 5 days. CON: control.
Effect of BMP-2 and titanium particles on the differentiation of osteoclast
precursors
BMP-2 is another cytokine that was reported recently to stimulate osteoclast
differentiation (8). Therefore, we
hypothesized that BMP-2 could affect the titanium particle-induced osteoclast
formation of RAW 264.7 cells in the presence of RANKL. We used real-time PCR to
examine the expression of the osteoclast marker genes NFATc1,
TRAP, and Cathepsin K (31-33). The cells were
pretreated with RANKL (30 ng/mL) for 1 h and subsequently treated or not with 50
ng/mL BMP-2 alone, 150 µg/mL titanium particles alone, or BMP-2 and titaniumfor 5
days. The PCR analysis showed that neither BMP-2 nor the titanium particles can
significantly enhance the expression of all these osteoclastogenesis-related genes in
the presence of RANKL (Figure 2). Surprisingly,
however, we found that adding BMP-2 and titanium particles together greatly enhanced
the expression of the TRAP, Cathepsin K and
NFATc1 genes (Figure 2).
TRAP staining confirmed these results. Many large, multinucleated TRAP-positive cells
were detected in the cultures treated with both BMP-2 and titanium particles. Only
small, mononucleated cells were observed in the titanium particles and RANKL
treatment (Figure 3).
Figure 2
BMP-2 and titanium (Ti) particles synergistically activated osteoclast
formation. Gene relative expression was determined by real-time PCR; RAW 264.7
cells were cultured with suboptimal (30 ng/mL) RANKL, BMP-2 (50 ng/mL) or Ti
particles (150 µg/mL) as indicated for 5 days. A,
TRAP gene expression. B,
NFATc1 gene expression. C,
Cathepsin K gene expression. Data are reported as means±SD.
*P<0.01; **P<0.0001 (one-way ANOVA).
Figure 3
TRAP staining of RAW 264.7 cells-derived osteoclasts differentiated with 30
ng/mL RANKL, 50 ng/mL BMP-2, or 150 µg/mL titanium (Ti) particles for 5 days.
TRAP-positive multinucleated cells (arrows) were observed in the RANKL+Ti and
RANKL+Ti+BMP. No TRAP-positive multinucleated cells were observed in control
and RANKL+BMP.
To further confirm this synergy between BMP-2 and the titanium particles, we
prolonged the culture time from 5 to 7 days. We treated the RAW 264.7 cells with
RANKL or not and then added the titanium particles and different concentrations of
BMP-2. After 7 days of culture, we performed real-time PCR to measure
TRAP gene expression. We found that BMP-2 greatly enhanced
osteoclast formation, with a peak at 50 ng/mL and to a lesser extent at higher
concentrations. There was no expression of the TRAP gene in the
absence of RANKL (Figure 4). TRAP staining
showed that abundant TRAP-positive multinucleated cells appeared when the cells were
treated with BMP-2 from low to high doses in the presence of RANKL (Figure 5A). No TRAP-positive multinucleated cells
were observed in the absence of RANKL (data not shown). These results are quantified
in Figure 5B and C, and show that BMP-2 greatly
increased the number and average size of the osteoclasts in the RAW 264.7 cells to
levels several-fold greater than by the stimulation with titanium particles and
RANKL. In addition, the pit formation assay revealed that the bone resorptive
activity of mature osteoclasts was significantly accelerated when treated with BMP-2
(Figure 5D). These data indicated that
BMP-2, even at a low concentration, synergized with titanium particles and RANKL to
enhance the differentiation of osteoclast precursors. BMP-2 may be a crucial factor
in the titanium particle-mediated osteoclast formation.
Figure 4
Effects of BMP-2 on titanium particles-mediated osteoclast formation.
Real-time PCR showed the expression of TRAP. The RAW 264.7 cells were
pretreated with 150 µg/mL titanium particles and different concentrations of
BMP-2 for 1 h, then treated or not with 30 ng/mL RANKL for 7 days. CON:
control. Data are reported as means±SD. ***P<0.001 (one-way ANOVA).
Figure 5
TRAP staining of RAW 264.7 cells-derived osteoclast formation.
A, RAW 264.7 cells were treated with 30 ng/mL RANKL and 150
µg/mL titanium particles for 1 h, then treated with BMP-2 for 7 days.
Quantitative analysis showing the number of osteoclasts per well
(B), the average size of the 10 largest osteoclasts in each
well (C) and the pit resorption area per well
(D). Data are reported as means±SD. *P<0.05; **P<0.01
***P<0.001 (one-way ANOVA).
Effect of BMP-2 and titanium particles on cell viability
The MTT assay was used to determine whether BMP-2 and titanium particles induced the
enhancement of proliferation and viability of RAW 264.7 cells. The cells treated with
50 ng/mL BMP-2 and titanium particles showed a slight, nonsignificant decrease of
cell viability. However, neither BMP-2 nor the titanium particles showed any
cytotoxic effects on the RAW 264.7 cells compared with the control (Figure 6). Based on these findings, we concluded
that neither BMP-2 nor the titanium particles increased RAW 264.7 macrophage-like
cell proliferation.
Figure 6
Neither the BMP-2 nor titanium (Ti) particles affect RAW 264.7 cell
proliferation. RAW 264.7 cells (control, con) were pretreated with 30 ng/mL
RANKL and 150 µg/mL Ti particles for 1 h, then treated or not with 50 ng/mL
BMP-2 for 3 days. Data are reported as means±SD cell proliferation as the
absorbance ratio at 490 nm.
Expression of BMP-2 signaling during osteoclast differentiation
To confirm that BMP-2 acted directly upon the osteoclast precursors, we performed
Western blotting against c-Fos and p-SMAD 1/5/8. c-Fos is well known to be essential
for RANKL-mediated osteoclast differentiation and to be expressed in the early stages
of osteoclast formation (34). Therefore, we
observed it from days 2 to 5. As shown in Figure
7, the expression of c-Fos was strongly detected from days 2 to 5 when
treated with BMP-2. In contrast, in the absence of BMP-2, the expression of c-Fos
decreased gradually over time. During the expression of c-Fos, p-SMAD 1/5/8 was
constantly expressed at high levels throughout osteoclast differentiation when
treated with BMP-2, and p-SMAD 1/5/8 was only weakly detected when BMP-2 was absent
(Figure 7). These results strongly indicated
that BMP-2 signaling was involved in osteoclast differentiation and that BMP signal
transduction may play a crucial role in the differentiation of osteoclasts.
Figure 7
Western blot showed the expression of phospho-SMAD (p-SMAD) 1/5/8 and
c-Fos. RAW 264.7 cells were treated with 30 ng/mL RANKL and 150 µg/mL titanium
particles for 1 h and subsequently treated or not with 50 ng/mL BMP-2 at
indicated times.
Effect of titanium particles on BMP-induced SMAD phosphorylation during
osteoclastogenesis
Previous reports have shown that the BMP-2/SMAD and TNF-α/NF-κB systems appear to
exert antagonistic effects (35). Thus, we
hypothesized that the titanium particles could inhibit BMP-induced SMAD
phosphorylation. As shown in Figure 8A, the RAW
264.7 cells were pretreated with BMP-2 for 1 h and then treated with or without
titanium particles. BMP-2 increased p-SMAD 1/5/8 protein expression, which peaked at
12 h in both the titanium particle and nonparticle groups; there was no significant
difference between the two groups. This result showed that the secretion of TNF-α
induced by the titanium particles did not affect BMP-induced SMAD phosphorylation in
RAW 264.7 cells (Figure 8A).
Figure 8
Titanium (Ti) particles do not affect phospho-SMAD (p-SMAD) 1/5/8
expression. BMP-2 does not affect expression of TNF-α. A, RAW
264.7 cells were treated with 30 ng/mL RANKL and 50 ng/mL BMP-2 for 1 h, then
treated with or without 150 µg/mL Ti particles at indicated times.
B, ELISA showed the expression of TNF-α. RAW 264.7 cells
(control) were treated with 30 ng/mL RANKL and 150 µg/mL Ti particles for 1 h,
then treated or not with 50 ng/mL BMP-2 for 24 h. Data are reported as
means±SD. *P<0.05 (one-way ANOVA).
Secretion of TNF-α from RAW 264.7 cells treated with BMP-2 and titanium
particles
Hong et al. (36) reported that BMP-6 induced
the expression of TNF-α of RAW 264.7 cells. To determine whether BMP-2 had the same
effect, we performed ELISA to observe the expression of TNF-α. As shown in Figure 8B, although TNF-α was greatly increased in
the titanium particle and titanium particle-BMP-2 groups, there was no significant
difference between these two groups, demonstrating that BMP-2 did not increase TNF-α
expression.
BMP-2 regulates the expression of SMAD-independent pathways in titanium
particle-meditated osteoclast differentiation
We further investigated signaling pathways other than the SMAD pathways that could be
activated by BMP-2. We detected the expression of p-P38, p-IkB, and p-JNK by Western
blotting, and found that the RAW 264.7 cells expressed elevated levels of p-P38 and
p-IkB in a time-dependent manner in the presence of BMP-2 and that the expression of
these proteins was lowered without BMP-2 treatment (Figure 9A). There was no significant difference in the expression of p-JNK
between the two groups. To further confirm the effect of BMP-2 on the activation of
p-IkB, we evaluated the expression of P50, an NF-κB subunit. The result showed that
BMP-2 increased nuclear translocation of P50 compared with the group without BMP-2
treatment (Figure 9B). These results
demonstrate that BMP-2 synergized with the titanium particles in osteoclastogenesis
by directly stimulating the expression of p-JNK, p-P38, p-IkB, and P50.
Figure 9
BMP-2 regulates expression of p-JNK, p-IkB, p-P38, and P50.
A, RAW 264.7 cells were treated with RANKL and titanium
particles for 1 h, then treated or not with BMP-2 at indicated times. p-JNK,
p-IkB, and p-P38 were detected by Western blot. B, BMP-2
regulates expression of P50. RAW 264.7 cells were treated with RANKL and
titanium particles for 1 h, and then treated with or without BMP-2 at indicated
times.
Discussion
Not all RAW 264.7 cell lines or passages will form osteoclasts (30). In this study, we confirmed that titanium particles at
different concentrations could not induce osteoclast differentiation in the presence of
RANKL.Although the role of BMP-2 in promoting osteoblast differentiation has been extensively
investigated, and it has been approved by the FDA as an alternative to bone grafts in
long bone fractures and healing in a number of orthopedic and maxillofacial applications
(37), its function in particle-induced aseptic
loosening and osteolysis has not yet been elucidated. Jager et al. (38) showed that a local BMP-2/mesenchymal stem cell
application can promote bone formation within a wear debris-induced periprosthetic
osteolytic area, but there was no evidence that the BMP-2 application was solely
responsible for healing the severe osteolysis. Quinn et al. (39) reported that TGF-β greatly increased osteoclast formation in
RAW 264.7 macrophage-like cells to levels that were several-fold greater than those
attainable with maximal stimulation by RANKL or TNF-α. In this study, we demonstrated
that BMP-2 was not sufficient to increase osteoclast formation. However, BMP-2 greatly
enhanced titanium particle-meditated osteoclast formation in the presence of RANKL. This
treatment increased the size and number of multinuclear osteoclasts, the expression of
osteoclast genes (TRAP and NFATc1), and the resorption
area. At a low concentration (50 ng/mL), BMP-2 appears to have an optimal effect on
stimulation of osteoclast formation. However, no multinucleated cells were observed in
the absence of RANKL.Although RANKL and titanium particles could induce c-Fos expression, more c-Fos was
detected in the group treated with BMP-2 and titanium particles from days 2 to 5 in the
presence of RANKL. Our data also showed that BMP-2 treatment increased SMAD
phosphorylation following the high expression of c-Fos throughout the early stages of
osteoclastogenesis. Moreover, the phosphorylated SMAD levels were negligible in the
titanium particle groups. All these findings imply that BMP-2 activated osteoclast
formation by increasing c-Fos expression and that the BMP-dependent pathway was at least
implicated in titanium particle-induced osteoclastogenesis.Macrophages are well known to respond to the titanium particle challenge in two distinct
ways. First, the wear debris activates proinflammatory signaling. Second, it activates
MAPK cascades as well as NF-κB and other transcription factors. Both actions contribute
to an increase of osteoclast recruitment. In our study, we first demonstrated that BMP-2
did not increase the expression of TNF-α, the major proinflammatory factor in
inflammatory osteolysis. Then, our data showed that BMP-2 stimulated the expression of
p-JNK, p-P38, and p-IkB, and the increase in p-IkB explains the progressive increase in
P50. In addition to the canonical SMAD-dependent pathway, BMP has been reported to
activate MAPK pathways in some systems (40).
Nakashima et al. (22) reported that titanium
particles can induce the rapid activation of MAPK family members. Our data showed that
titanium particles did not affect the expression of BMP-induced SMAD phosphorylation.
Although the titanium particles slightly enhanced the levels of these signaling
pathways, they were insufficient to induce osteoclast formation unless BMP-2 was also
added. This result suggests that BMP-2 did not increase the titanium particle-induced
osteoclastogenesis by activating the expression of proinflammatory cytokines but instead
acted upon downstream signaling pathways, such as p-JNK, p-P38, and p-IkB. Thus, the
effect of BMP-2 in the wear debris-induced osteoclastogenesis has been
underestimated.In summary, this study suggests that synergy of BMP-2 and titanium particles enhanced
osteoclast formation in the presence of RANKL by increasing the expression of p-JNK,
p-P38, and p-IkB. BMP-2 may be a crucial factor in titanium particle-mediated osteoclast
formation.
Authors: Y Nakashima; D H Sun; M C Trindade; W J Maloney; S B Goodman; D J Schurman; R L Smith Journal: J Bone Joint Surg Am Date: 1999-05 Impact factor: 5.284
Authors: J M Quinn; K Itoh; N Udagawa; K Hausler; H Yasuda; N Shima; A Mizuno; K Higashio; N Takahashi; T Suda; T J Martin; M T Gillespie Journal: J Bone Miner Res Date: 2001-10 Impact factor: 6.741
Authors: M L Falany; A M Thames; J M McDonald; H C Blair; M A McKenna; R E Moore; M K Young; J P Williams Journal: Biochem Biophys Res Commun Date: 2001-02-16 Impact factor: 3.575
Authors: Eric D Jensen; Lan Pham; Charles J Billington; Kelly Espe; Ann E Carlson; Jennifer J Westendorf; Anna Petryk; Rajaram Gopalakrishnan; Kim Mansky Journal: J Cell Biochem Date: 2010-03-01 Impact factor: 4.429